Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 12/20 | 0.39 |
| ▸ | AR | P10275 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29849115 | 0.78 | CA12 (0.36) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL28162172 | 0.74 | GRIN1 (0.32) | MEN1PKMKMT2A | |
| SCHEMBL27876356 | 0.74 | MEN1 (0.31) | MEN1PKMKMT2A | |
| SCHEMBL2002285 | 0.73 | AR (0.54) | PGRAR | |
| SCHEMBL11316991 | 0.70 | — | — | |
| SCHEMBL26750150 | 0.70 | GRM2 (0.38) | MEN1PKMKMT2A | |
| SCHEMBL23662560 | 0.69 | CYP1A2 (0.39) | MEN1PKMKMT2ACA12BRD4 | |
| SCHEMBL24799594 | 0.68 | AR (0.44) | PGRAR | |
| SCHEMBL22579369 | 0.68 | MEN1 (0.43) | MEN1PKMKMT2APGRAR | |
| SCHEMBL24196471 | 0.67 | AR (0.41) | PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3733662-B1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-107001328-A | Pyridin-2 (1H) -one quinolinone derivatives as mutant isocitrate dehydrogenase inhibitors | 福马治疗股份有限公司 | 2017-08-01 | — | — | CN | claimed |
| EP-3194376-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-07-26 | — | — | EP | claimed |
| WO-2016044789-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | claimed |
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4216948-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | Cardurion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3733662-B1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11311527-B2 | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) | FORMA THERAPEUTICS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022067082-A1 | FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS | CARDURION PHARMACEUTICALS, LLC (US) | 2022-03-31 | — | — | WO | disclosed |
| CN-107001328-A | Pyridin-2 (1H) -one quinolinone derivatives as mutant isocitrate dehydrogenase inhibitors | 福马治疗股份有限公司 | 2017-08-01 | — | — | CN | disclosed |
| EP-3194376-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044789-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | CDK9, AURKB, AURKC | MEN1 3572/4885PKM 1816/4885KMT2A 1210/4885 |
| US-11311527-B2 | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) | IDH1, IDH3B, IDH2 | MEN1 217/4885PKM 2506/4885KMT2A 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.